Dexcom annual debt-to-ebitda ratio
2019
2020
2021
2022
2023
2024
2025
Dexcom Debt-to-EBITDA Ratio Growth & History (DXCM)
Dexcom's debt-to-ebitda ratio was 0.13 for fiscal 2025.
View full Dexcom company overviewDexcom annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.13 | −1.53 | −91.95% |
| 2024 | 2024-12-31 | 1.66 | 1.45 | +690.51% |
| 2023 | 2023-12-31 | 0.21 | −1.53 | −87.93% |
| 2022 | 2022-12-31 | 1.74 | 1.25 | +256.56% |
| 2021 | 2021-12-31 | 0.49 | −0.01 | −1.26% |
| 2020 | 2020-12-31 | 0.49 | −0.03 | −6.58% |
| 2019 | 2019-12-31 | 0.53 | — | — |
Dexcom quarterly debt-to-ebitda ratio
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.11 | −1.34 | −92.36% |
| Q1 2026 | 2026-03-31 | 0.11 | −1.46 | −92.94% |
| Q4 2025 | 2025-12-31 | 0.13 | −1.53 | −91.95% |
| Q3 2025 | 2025-09-30 | 1.31 | 1.13 | +624.44% |
| Q2 2025 | 2025-06-30 | 1.45 | 1.28 | +722.63% |
| Q1 2025 | 2025-03-31 | 1.57 | 1.39 | +763.48% |
| Q4 2024 | 2024-12-31 | 1.66 | 1.45 | +690.51% |
| Q3 2024 | 2024-09-30 | 0.18 | −0.24 | −57.44% |
| Q2 2024 | 2024-06-30 | 0.18 | −1.37 | −88.58% |
| Q1 2024 | 2024-03-31 | 0.18 | −1.51 | −89.27% |
| Q4 2023 | 2023-12-31 | 0.21 | −1.53 | −87.93% |
| Q3 2023 | 2023-09-30 | 0.42 | 0.03 | +8.44% |
| Q2 2023 | 2023-06-30 | 1.55 | 1.09 | +240.62% |
| Q1 2023 | 2023-03-31 | 1.69 | 1.23 | +265.06% |
| Q4 2022 | 2022-12-31 | 1.74 | 1.25 | +256.56% |
| Q3 2022 | 2022-09-30 | 0.39 | −0.00 | −0.23% |
| Q2 2022 | 2022-06-30 | 0.45 | 0.03 | +5.97% |
| Q1 2022 | 2022-03-31 | 0.46 | −0.01 | −2.36% |
| Q4 2021 | 2021-12-31 | 0.49 | −0.01 | −1.26% |
| Q3 2021 | 2021-09-30 | 0.39 | 0.06 | +17.85% |
| Q2 2021 | 2021-06-30 | 0.43 | 0.15 | +51.56% |
| Q1 2021 | 2021-03-31 | 0.47 | 0.10 | +25.25% |
| Q4 2020 | 2020-12-31 | 0.49 | −0.03 | −6.58% |
| Q3 2020 | 2020-09-30 | 0.33 | — | — |
| Q2 2020 | 2020-06-30 | 0.28 | — | — |
| Q1 2020 | 2020-03-31 | 0.38 | — | — |
| Q4 2019 | 2019-12-31 | 0.53 | — | — |
Dexcom debt-to-ebitda ratio trends
Over the last five fiscal years, Dexcom's debt-to-ebitda ratio decreased from 0.49 to 0.13, a change of −0.36. The latest reported quarter, Q2 2026, shows 0.11.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dexcom source filings ↗Community posts
Dexcom raises revenue and margin targets and authorizes a $1 billion buyback
Dexcom ($DXCM) lifted its 2026 sales forecast to $5.20–$5.25 billion, raising the midpoint, and increased its adjusted operating-margin target to approximately 24%. Third-quarter 2026 revenue increased 11% to $1.34 billion, with US growth o ...
